Laura Ripin
, Executive Director, Business Development and Licensing, Novartis
Laura Ripin is an accomplished business development leader with over 20 years of experience negotiating complex strategic transactions across various sectors, including pharma, biotech, and not-for-profit organizations. Laura joined Novartis in 2010 and has assumed diverse BD&L roles of increasing responsibility. She has led end-to-end BD&L across Search and Evaluation, Transactions and Alliance Management in Precision Medicine, Oncology, and Hematology, and currently serves as the Head of Business Development and Licensing Transactions for Neuroscience. Throughout her tenure at Novartis, she successfully negotiated several strategic partnerships, including with Matchpoint Therapeutics in 2025, Vyriad and Dren Bio in 2024, and multiple Companion Diagnostic Development and Commercialization agreements with Ventana, Qiagen, Agilent, Roche, and others over the years. Before joining Novartis, Laura served as Director of Business Development and Licensing for Genzyme Genetics’ Reproductive and Prenatal Health diagnostics business and led BD&L activities for MGH Brigham’s Precision Medicine Center. Laura began her licensing career in academic technology transfer as a Team Leader and Senior Licensing Officer at Massachusetts General Hospital. She holds a Master’s degree in Biological and Biomedical Sciences, Genetics from Harvard University and a Bachelor of Sciences degree in Biology from Emory University.
